8-chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione tris(hydroxylmethyl)aminomethane salt manufacturers
- GSK256073 Tris
-
- $2500.00
-
2026-05-11
- CAS:1228650-42-7
- Purity:
- Supply Ability: 10g
|
| | 8-chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione tris(hydroxylmethyl)aminomethane salt Basic information |
| | 8-chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione tris(hydroxylmethyl)aminomethane salt Chemical Properties |
| | 8-chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione tris(hydroxylmethyl)aminomethane salt Usage And Synthesis |
| Description | GSK256073 is an agonist of G-protein coupled receptor 109A (GPR109A). It acts by reducing serum glucose in subjects with type 2 diabetes mellitus. | | Uses | GSK256073 tris is a potent, selective and orally active GPR109A agonist and a long-lasting and non-flushing HCA2 full agonist with a pEC50 of 7.5 (human HCA2). GSK256073 tris acutely improves glucose homeostasis via inhibition of lipolysis and has the potential for the study of type 2 diabetes mellitus (T2DM)and dyslipidemia[1][2]. GPR109A: G-protein coupled receptor 109A; HCA2: hydroxy-carboxylic acid receptor 2 | | References | [1] Dobbins RL, et al. GSK256073, a selective agonist of G-protein coupled receptor 109A (GPR109A) reduces serum glucose in subjects with type 2 diabetes mellitus.Diabetes Obes Metab.2013 Nov;15(11):1013-21. DOI:10.1111/dom.12132 [2] Sprecher D, et al. Discovery and characterization of GSK256073, a non-flushing hydroxy-carboxylic acid receptor 2 (HCA2) agonist.Eur J Pharmacol. 2015 Jun 5;756:1-7. DOI:10.1016/j.ejphar.2015.01.051 |
| | 8-chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione tris(hydroxylmethyl)aminomethane salt Preparation Products And Raw materials |
|